Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 22, 2023

Durvalumab for BCG-Unresponsive Urothelial Carcinoma In Situ of the Bladder

Clinical Cancer Research


Additional Info

Clinical Cancer Research
A Phase 2 Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder
Clin. Cancer Res 2023 Jul 28;[EPub Ahead of Print], R Li, WJ Sexton, J Dhillon, A Berglund, S Naidu, G Borjas, K Rose, Y Kim, X Wang, JR Conejo-Garcia, RK Jain, MA Poch, PE Spiess, J Pow-Sang, SM Gilbert, J Zhang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading